Insmed Incorporated (BST:IM8N)

Market Cap	23.18B
Revenue (ttm)	338.99M
Net Income (ttm)	-880.74M
Shares Out	n/a
EPS (ttm)	-4.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2
Open	93.00
Previous Close	94.00
Day's Range	93.00 - 93.50
52-Week Range	55.00 - 98.00
Beta	n/a
RSI	77.17
Earnings Date	Aug 7, 2025

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 1,271
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: IM8N

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD